The Effect of Antiemetics on Bowel Preparation Before Colonoscopy

NCT ID: NCT04583111

Last Updated: 2020-10-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-01

Study Completion Date

2022-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Polyethylene glycol (PEG) is one of the most common laxatives used in colonoscopy. However, 5 - 15% of patients can not complete the preparation due to its poor taste and large volume. So this study is aimed to explore the effect of antiemetics on abdominal discomforts associated with PEG.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bowel Preparation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Domperidone group

Patients in Domperidone group took 10mg of domperidone 30min before PEG.

Group Type EXPERIMENTAL

Domperidone

Intervention Type DRUG

Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.

Sulpiride group

Patients in Sulpiride group took 100mg of sulpiride 30min before PEG.

Group Type EXPERIMENTAL

sulpiride

Intervention Type DRUG

Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.

Control group

Patients in Control group followed the regular routine of 3L split-dose of PEG.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Domperidone

Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.

Intervention Type DRUG

sulpiride

Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-70 years patients scheduled for colonoscopy

Exclusion Criteria

* intestinal obstruction or hemorrhage;
* allergy to domperidone, sulpiride or PEG;
* pregnancy or breastfeeding;
* previous use of prokinetics within 1 month.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

RenJi Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shengliang Chen

Deputy director of the Division of Gastroenterology and Hepatology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shengliang Chen

Shanghai, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Shengliang Chen, Dr

Role: CONTACT

02158752345

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Shengliang Chen

Role: primary

02158752345

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RJYYXHNK-006

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.